[go: up one dir, main page]

MX2019011485A - Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein. - Google Patents

Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein.

Info

Publication number
MX2019011485A
MX2019011485A MX2019011485A MX2019011485A MX2019011485A MX 2019011485 A MX2019011485 A MX 2019011485A MX 2019011485 A MX2019011485 A MX 2019011485A MX 2019011485 A MX2019011485 A MX 2019011485A MX 2019011485 A MX2019011485 A MX 2019011485A
Authority
MX
Mexico
Prior art keywords
antagonist
pharmaceutical composition
histamine
combination
receptor protein
Prior art date
Application number
MX2019011485A
Other languages
Spanish (es)
Inventor
Velasco López Laura
Daniel Walls Flores Oliver
Original Assignee
Laboratorios Liomont Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Liomont Sa De Cv filed Critical Laboratorios Liomont Sa De Cv
Priority to MX2019011485A priority Critical patent/MX2019011485A/en
Publication of MX2019011485A publication Critical patent/MX2019011485A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses a pharmaceutical composition comprising a leukotriene antagonist in combination with an antagonist of the histamine H-1 receptor protein. Herein, the pharmaceutical composition is adapted in a unit dose form and the leukotriene is not mixed with the histamine H-1 receptor. Also, the pharmaceutical composition is useful for the treatment of symptoms related to rhinitis, asthma, and other allergic conditions.
MX2019011485A 2019-09-26 2019-09-26 Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein. MX2019011485A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2019011485A MX2019011485A (en) 2019-09-26 2019-09-26 Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019011485A MX2019011485A (en) 2019-09-26 2019-09-26 Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein.

Publications (1)

Publication Number Publication Date
MX2019011485A true MX2019011485A (en) 2020-01-10

Family

ID=72039307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011485A MX2019011485A (en) 2019-09-26 2019-09-26 Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein.

Country Status (1)

Country Link
MX (1) MX2019011485A (en)

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
MX387530B (en) ANTI-CGRP RECEPTOR ANTIBODY FOR USE IN TREATING OR PREVENTING MIGRAINE HEADACHE.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX391339B (en) PHARMACEUTICAL COMPOSITION INCLUDING SELEXIPAG.
BR112013027034A2 (en) "pharmaceutical compositions comprising digestive enzymes and their use".
MX2017003215A (en) Cenicriviroc combination therapy for the treatment of fibrosis.
MX2018003179A (en) Cenicriviroc combination therapy for the treatment of fibrosis.
MX2024001849A (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia.
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MY199557A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
MX2021005945A (en) Cyclic Ureas.
BR112018007947A2 (en) use of ep4 receptor antagonists for the treatment of liver cancer associated with nash
MX2020010568A (en) Fused cyclic urea derivatives as crhr2 antagonist.
MX2024013184A (en) Methods and compositions for treating sleep apnea
PE20191240A1 (en) FORMS OF PHARMACEUTICAL ADMINISTRATION CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS AND THEIR USE FOR THE TREATMENT OF RESPIRATORY DISORDERS
PH12021550671A1 (en) Prodrugs of cgrp antagonists
BR112017013998A2 (en) New Benzimidazole Derivatives as Antihistamines
MX2019011485A (en) Stabilized pharmaceutical composition for the administration of a leukotriene antagonist in combination with an antagonist of the histamine h-1 receptor protein.
EA201892529A1 (en) COMBINATION OF PURE ANTAGONISTS OF 5-HTRECEPTORS WITH ACETYLHOLINESTERASE INHIBITORS
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX378799B (en) COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH AN NMDA RECEPTOR ANTAGONIST.
MY203365A (en) Montelukast for the treatment of erosive hand osteoarthritis
AU2019253577A1 (en) Oxytocin compositions and methods of use
MX2024000777A (en) Pharmaceutical composition of limited moisture transmission for the administration of a leukotriene antagonist in combination with a histamine h-1 receptor protein antagonist.
MX2018011699A (en) A synergistic pharmaceutical composition of leukotriene receptor antagonist and a histamine h1 inverse agonist.